The nexletol market size has grown rapidly in recent years. It will grow from $2.81 billion in 2024 to $3.21 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The historical growth can be attributed to the rising prevalence of hypercholesterolemia, increased awareness of cardiovascular risks, growing demand for alternatives to statins, higher incidence of statin intolerance, and increased adoption of oral lipid-lowering therapies.
The nexletol market size is expected to see rapid growth in the next few years. It will grow to $5.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. Factors driving this growth include a greater focus on preventive healthcare, the increasing prevalence of dyslipidemia, the adoption of digital health technologies, broader global market access, and a rise in clinical approvals and label expansions. Key trends anticipated during the forecast period include advancements in digital health for remote patient monitoring, development of triple combination therapies to enhance LDL-C reduction, innovations in personalized medicine for cholesterol treatment, integration of telemedicine platforms to improve patient access, and progress in clinical trials supporting expanded label indications.
The rising incidence of cardiovascular diseases is expected to drive the growth of the Nexletol market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The surge in these conditions is primarily linked to increasingly sedentary lifestyles, which contribute to weight gain, metabolic imbalances, and elevated blood pressure, thereby heightening the risk of heart-related issues. Nexletol plays a crucial role in managing cardiovascular diseases by lowering low-density lipoprotein (LDL) cholesterol levels, which helps prevent plaque buildup in arteries and reduces the likelihood of heart attacks and other cardiovascular events. For instance, in January 2025, a report published by the American Heart Association, a US-based nonprofit organization, revealed that the United States recorded 941,652 deaths due to cardiovascular disease in 2022, an increase of over 10,000 compared to 931,578 CVD-related deaths in 2021. This upward trend underscores the growing demand for treatments like Nexletol.
Key players in the Nexletol market are increasingly focusing on the development of advanced non-statin therapies as effective alternatives for cholesterol management. Non-statin therapies refer to treatments that lower cholesterol or manage cardiovascular risk without relying on statin medications. For example, in August 2022, Esperion Therapeutics, a US-based pharmaceutical firm, announced that bempedoic acid (NEXLETOL) received recognition from the American College of Cardiology (ACC) as a significant oral non-statin option for reducing LDL-cholesterol in patients with atherosclerotic cardiovascular disease (ASCVD). This endorsement, issued by the ACC's Task Force on Expert Consensus Decision Pathways (ECDP), highlights bempedoic acid’s value, particularly for patients who cannot tolerate statins, reinforcing its expanding role in cardiovascular treatment.
In May 2025, HLS Therapeutics, a pharmaceutical company based in Canada, entered into a partnership with Esperion Therapeutics to commercialize Nexletol. The collaboration is aimed at expanding the accessibility of Nexletol and Nexlizet in Canada, offering additional treatment options for individuals with elevated LDL-C levels, especially those who are intolerant to statins or unable to achieve their LDL-C targets with existing therapies. Esperion Therapeutics, based in the United States, is the developer of NEXLETOL.
Major players in the nexletol market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, Divi’s Laboratories Limited, Esperion Therapeutics Inc., and Neopharm Inc.
North America was the largest region in the nexletol market in 2024. The regions covered in nexletol report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nexletol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Nexletol is a medication that functions by targeting and inhibiting a specific enzyme involved in cholesterol production in the liver. Its primary use is to reduce low-density lipoprotein cholesterol (LDL-C), often referred to as bad cholesterol, in adults with certain cardiovascular conditions.
The main types of Nexletol include the 180mg dosage and other variations. The 180mg refers to a specific strength of the medication, indicating the amount of active ingredient per dose. It can be administered through oral, injectable, or intravenous routes and is used for treating conditions such as hyperlipidemia, atherosclerosis, and cardiovascular disease. Nexletol is utilized by various end-users, including hospitals, clinics, and homecare settings.
The nexletol market research report is one of a series of new reports that provides nexletol market statistics, including the nexletol industry global market size, regional shares, competitors with the nexletol market share, detailed nexletol market segments, market trends, and opportunities, and any further data you may need to thrive in the nexletol industry. This nexletol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The nexletol market consists of sales of non-statin lipid-lowering agents, dietary supplements, and cholesterol absorption inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The nexletol market size is expected to see rapid growth in the next few years. It will grow to $5.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. Factors driving this growth include a greater focus on preventive healthcare, the increasing prevalence of dyslipidemia, the adoption of digital health technologies, broader global market access, and a rise in clinical approvals and label expansions. Key trends anticipated during the forecast period include advancements in digital health for remote patient monitoring, development of triple combination therapies to enhance LDL-C reduction, innovations in personalized medicine for cholesterol treatment, integration of telemedicine platforms to improve patient access, and progress in clinical trials supporting expanded label indications.
The rising incidence of cardiovascular diseases is expected to drive the growth of the Nexletol market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The surge in these conditions is primarily linked to increasingly sedentary lifestyles, which contribute to weight gain, metabolic imbalances, and elevated blood pressure, thereby heightening the risk of heart-related issues. Nexletol plays a crucial role in managing cardiovascular diseases by lowering low-density lipoprotein (LDL) cholesterol levels, which helps prevent plaque buildup in arteries and reduces the likelihood of heart attacks and other cardiovascular events. For instance, in January 2025, a report published by the American Heart Association, a US-based nonprofit organization, revealed that the United States recorded 941,652 deaths due to cardiovascular disease in 2022, an increase of over 10,000 compared to 931,578 CVD-related deaths in 2021. This upward trend underscores the growing demand for treatments like Nexletol.
Key players in the Nexletol market are increasingly focusing on the development of advanced non-statin therapies as effective alternatives for cholesterol management. Non-statin therapies refer to treatments that lower cholesterol or manage cardiovascular risk without relying on statin medications. For example, in August 2022, Esperion Therapeutics, a US-based pharmaceutical firm, announced that bempedoic acid (NEXLETOL) received recognition from the American College of Cardiology (ACC) as a significant oral non-statin option for reducing LDL-cholesterol in patients with atherosclerotic cardiovascular disease (ASCVD). This endorsement, issued by the ACC's Task Force on Expert Consensus Decision Pathways (ECDP), highlights bempedoic acid’s value, particularly for patients who cannot tolerate statins, reinforcing its expanding role in cardiovascular treatment.
In May 2025, HLS Therapeutics, a pharmaceutical company based in Canada, entered into a partnership with Esperion Therapeutics to commercialize Nexletol. The collaboration is aimed at expanding the accessibility of Nexletol and Nexlizet in Canada, offering additional treatment options for individuals with elevated LDL-C levels, especially those who are intolerant to statins or unable to achieve their LDL-C targets with existing therapies. Esperion Therapeutics, based in the United States, is the developer of NEXLETOL.
Major players in the nexletol market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, Divi’s Laboratories Limited, Esperion Therapeutics Inc., and Neopharm Inc.
North America was the largest region in the nexletol market in 2024. The regions covered in nexletol report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nexletol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Nexletol is a medication that functions by targeting and inhibiting a specific enzyme involved in cholesterol production in the liver. Its primary use is to reduce low-density lipoprotein cholesterol (LDL-C), often referred to as bad cholesterol, in adults with certain cardiovascular conditions.
The main types of Nexletol include the 180mg dosage and other variations. The 180mg refers to a specific strength of the medication, indicating the amount of active ingredient per dose. It can be administered through oral, injectable, or intravenous routes and is used for treating conditions such as hyperlipidemia, atherosclerosis, and cardiovascular disease. Nexletol is utilized by various end-users, including hospitals, clinics, and homecare settings.
The nexletol market research report is one of a series of new reports that provides nexletol market statistics, including the nexletol industry global market size, regional shares, competitors with the nexletol market share, detailed nexletol market segments, market trends, and opportunities, and any further data you may need to thrive in the nexletol industry. This nexletol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The nexletol market consists of sales of non-statin lipid-lowering agents, dietary supplements, and cholesterol absorption inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Nexletol Market Characteristics3. Nexletol Market Trends And Strategies4. Nexletol Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market40 Mg32. Global Nexletol Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Nexletol Market34. Recent Developments In The Nexletol Market
5. Global Nexletol Growth Analysis And Strategic Analysis Framework
6. Nexletol Market Segmentation
80 Mg
7. Nexletol Market Regional And Country Analysis
8. Asia-Pacific Nexletol Market
9. China Nexletol Market
10. India Nexletol Market
11. Japan Nexletol Market
12. Australia Nexletol Market
13. Indonesia Nexletol Market
14. South Korea Nexletol Market
15. Western Europe Nexletol Market
16. UK Nexletol Market
17. Germany Nexletol Market
18. France Nexletol Market
19. Italy Nexletol Market
20. Spain Nexletol Market
21. Eastern Europe Nexletol Market
22. Russia Nexletol Market
23. North America Nexletol Market
24. USA Nexletol Market
25. Canada Nexletol Market
26. South America Nexletol Market
27. Brazil Nexletol Market
28. Middle East Nexletol Market
29. Africa Nexletol Market
30. Nexletol Market Competitive Landscape And Company Profiles
31. Nexletol Market Other Major And Innovative Companies
35. Nexletol Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Nexletol Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on nexletol market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for nexletol ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nexletol market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: 180mg; Other Types2) By Administration Route: Oral; Injectable; Intravenous
3) By Indication: Hyperlipidemia; Atherosclerosis; Cardiovascular Disease
4) By End User: Hospitals; Clinics; Homecare Settings
Subsegments:
1) By 180 mg: Prescription-based; Over-The-Counter (OTC); Hospital or clinic use; Long-Term care facilities use2) By Other Types: 40 mg; 80 mg; Other doses
Key Companies Profiled: Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Johnson & Johnson
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Daiichi Sankyo Company Limited
- Sun Pharmaceutical Industries Limited
- Menarini Group
- Dr. Reddy’s Laboratories Limited
- Zydus Lifesciences Limited
- Divi’s Laboratories Limited
- Esperion Therapeutics Inc.
- Neopharm Inc.